Hemolytic Uremic Syndrome of Childhood Clinical Trial
Official title:
Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital
Diarrhea-associated hemolytic uremic syndrome (D+HUS) is defined as a prodrome of enteritis followed by thrombocytopenia (< 150,000/mm3), microangiopathic hemolytic anemia, and signs of variable degrees of renal damage (increase in serum Cr, proteinuria, and/or hematuria) . Our aim is to detect the most reliable early predictors of poor prognosis to identify children at major risk of bad outcome who could eventually benefit from early specific treatments.
The disease is caused predominantly by Shiga toxin-producing enterohemorrhagic Escherichia
coli (STEC) and is one of the most common etiologies of acute kidney injury (AKI) and an
important cause of acquired chronic kidney disease in children [2]. The incidence of HUC
tends to parallel the seasonal fluctuation of E.coli o175 : H7 infection which peaks between
June & September. Nowadays, the incidence increases and is typically observe in infants and
children, especially those aged 6 months to 4 years. A complicated disease course is defined
as the development of one or more of the following manifestations: neurological dysfunction,
severe bowel injury, pancreatitis, hemodynamic instability (symptomatic hypotension,
multi-organ failure), cardiac (congestive heart failure, myocarditis, pericarditis,
arrhythmia) or pulmonary involvement (pulmonary edema, acute respiratory distress syndrome),
hematologic complications (hemorrhage), and death [1].
Many laboratory and clinical markers upon admission have been associated to severe forms of
the disease, including high initial leukocyte and hematocrit levels, major extrarenal
complications, dehydration and recently, the blood urea nitrogen (BUN) to serum creatinine
(Cr) ratio [1], [4-6]. Treatment of D+HUS remains supportive; thus, early identification of
high-risk patients can optimize their management [1-3].
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02205541 -
Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
|
Phase 3 |